Chest Department, Hopital de Mantes La Jolie, Mantes-la-Jolie, France.
Oncolgy Department, Centre Francois Baclesse, Caen, France.
Adv Ther. 2019 Aug;36(8):2161-2166. doi: 10.1007/s12325-019-01001-9. Epub 2019 Jun 1.
Mutation of human receptor tyrosine kinase epidermal growth factor receptor-2 (HER2) is a rare event, found in approximately 1% non-small cell lung cancers (NSCLC). The objective was to investigate the clinical characteristics and management of HER2-mutated NSCLCs in a real-life setting.
This multicenter study described NSCLCs harboring HER2 mutations diagnosed between January 2012 and December 2014, according their clinical characteristics, management, and outcomes: response rate (RR), progression-free survival (PFS), and overall survival (OS).
Thirty patients were included: 66.7% women; median age 65.2 ± 12 years; never or former smokers 73.3%. Of the stage IV patients (n = 23), 86% received first-line platin doublet chemotherapy: RR 61.5% and PFS 6.7 (95% CI 5.9-9.5) months; 52.1% received a second-line therapy: RR 18.2% and PFS 4.9 (95% CI 2.5-11.9) months. Median OS of stage IV was 10.7 months and 2-year OS was 27.2% (95% CI 11.7-63.2). All patients with stage I-III NSCLCs were alive at 2 years.
The rarity of HER2-mutated NSCLCs requires specific studies.
人类受体酪氨酸激酶表皮生长因子受体 2（HER2）的突变是一种罕见事件，约占非小细胞肺癌（NSCLC）的 1%。本研究旨在探讨真实环境中 HER2 突变型 NSCLC 的临床特征和治疗策略。
该多中心研究描述了 2012 年 1 月至 2014 年 12 月期间诊断为 HER2 突变的 NSCLC 患者的临床特征、治疗和结局，包括：客观缓解率（RR）、无进展生存期（PFS）和总生存期（OS）。
共纳入 30 例患者：66.7%为女性；中位年龄 65.2±12 岁；从不吸烟者或曾经吸烟者占 73.3%。23 例Ⅳ期患者中，86%接受了一线铂类双药化疗：RR 为 61.5%，PFS 为 6.7（95%CI 5.9-9.5）个月；52.1%接受二线治疗：RR 为 18.2%，PFS 为 4.9（95%CI 2.5-11.9）个月。Ⅳ期患者的中位 OS 为 10.7 个月，2 年 OS 为 27.2%（95%CI 11.7-63.2）。所有Ⅰ-Ⅲ期 NSCLC 患者在 2 年内均存活。
HER2 突变型 NSCLC 非常罕见，需要专门的研究。
